Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03323658 · ClinicalTrials.gov registry record · Phase 1
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03323658 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants.
The verdict
NCT03323658, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.
Interventions
- OTHER Questionnaire Administration
- DRUG Bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2022-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03323658
The ClinicalTrials.gov registry entry for NCT03323658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT03323658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03323658 about?
NCT03323658 is a clinical study titled "Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer". This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.
What is the current status of trial NCT03323658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-06-15. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT03323658?
The interventions under investigation include: Questionnaire Administration (OTHER), Bexarotene (DRUG).
Who is sponsoring clinical trial NCT03323658?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.